The problem...and the opportunity

Despite the significant growth of checkpoint inhibitors for the treatment of cancer, several challenges remain including significant side effects, limited efficacy, and a lack of personalization. There is a pressing need for therapies that can precisely target the underlying biological mechanisms of disease, offering both greater effectiveness and fewer side effects. Thus, the opportunity...